Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

STERIS plc (STE) Guidance & Earnings Results

On 2026-08-05 STERIS plc reaffirmed guidance: "Revenue growth 7-8% reported, 6-7% constant currency organic; adjusted EPS…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

STESTERIS plcFollow STE — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
22.6B
P/E TTM
28.4
Dividend yield
1.1%
52-week
—
Next earnings
5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
5 Aug 26ReaffirmedRevenue growth 7-8% reported, 6-7% constant currency organic; adjusted EPS $11.10-$11.30 · full year
11 May 26RaisedFY2027 adjusted EPS $11.10-11.30 (+9-11%) · full year
4 Feb 26ReaffirmedRevenue growth 8-9%; constant currency organic revenue growth 7-8%; adjusted EPS $10.15-$10.30 · full year
5 Nov 25RaisedFY26 organic revenue growth 7-8% (prior 6-7%); adjusted EPS $10.15-$10.30 (prior $9.90-$10.15); FCF ~$850M (prior $820M) · full year

STERIS plc — questions

What guidance did STERIS plc give?
On 2026-08-05: "Revenue growth 7-8% reported, 6-7% constant currency organic; adjusted EPS $11.10-$11.30"
When does STERIS plc report earnings?
STERIS plc's next earnings report is expected on 2026-11-05.

Every figure on this page comes from STERIS plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.